Introduction
TGFb superfamily members are involved in multiple, mainly cell type-dependent cellular functions aecting dierentiation, cell survival, and cell proliferation (Massague, 1990) . In epithelial cells, TGFbs cause a reversible cell growth arrest in G1 phase (Polyak, 1996; Sporn and Roberts, 1992) . Growth inhibitory, immunosuppressive, and apoptotic eects, characterize TGFb as a tumor suppressor. Naturally occurring inactivating mutations in TGFb receptors in human tumors support such a role for TGFb (Massague, 1998) .
TGFb 1 represents the prototype of the transforming growth factor b superfamily. The ligand binds to the type II receptor (TGFbRII), which heterodimerizes with a type I receptor. As a consequence, the type I protein is phosphorylated at serine/threonine residues by the constitutive active kinase-domain of the type II receptor, thereby inducing a number of intracellular signals (Attisano et al., 1993; Ebner et al., 1993; Franzen et al., 1993 ; recently reviewed in Piek et al., 1999) . The best characterized signal pathway mediated by TGFb is the phosphorylation and activation of Smad2/3 proteins (Heldin et al., 1997; Heldin and Ostman, 1996) . Activated Smad2/3 bind to Smad4, translocates into the nucleus, and regulates gene expression (Attisano and Wrana, 1998) . Subsequently, expression of cyclic D1 and cdk4, which are essential for cell cycle progression, is downregulated (Ewen et al., 1993; Ko et al., 1998) , whereas transcription of genes coding for collagen and other extracellular matrix proteins is enhanced (Roberts et al., 1990) . Moreover, TGFbRII seems to cooperate directly with cell cycle proteins, such as cyclin B, representing an additional way to inhibit cell proliferation (Liu et al., 1999) .
In addition to directly aecting cyclin and cyclindependent kinases, TGFb receptors are binding partners for other proteins with signaling properties, such as the immunophilin FKBP-12 (Chen et al., 1997) or the a subunit of farnesylprotein transferase (FTa). Upon receptor activation FTa is phosphorylated by type I receptor. FTa is able to modify a series of molecules including the small GTPase Ras (Kawabata et al., 1995; Wang et al., 1996) .
The Ras-Raf-ERK/MAPK-cascade is one major signaling pathway regulating cell proliferation in many cell types Pages et al., 1993) . Binding of growth factors, like EGF, FGF, or HGF to their corresponding receptor tyrosine kinases results in association of the receptor with adaptor proteins Grb2 and Sos, followed by activation of the small GTPase Ras. GTP-bound Ras catalyzes the translocation of Raf to the plasma membrane, where the activated kinase phosphorylates the MAP kinase kinase MEK. MEK in turn phosphorylates the extracellular signalregulated kinases ERK1 and ERK2 (Seger and Krebs, 1995) . Activated ERKs translocate into the nucleus and stimulate gene expression by triggering transcription factors like ELK1 and ATF-2 (Brunet et al., 1999; Chen et al., 1992; Zheng and Guan, 1994) . The ability of activation ERK kinases to phosphorylate Smads and thereby inactivating TGFb-or BMP-induced gene expression was recently described by Kretzschmar and coworkers (Kretzschmar et al., 1997 (Kretzschmar et al., , 1999 . These results suggest a crosstalk between Ras/Raf/ERK-and TGFb-mediated proliferation control via Smad.
Our results obtained in pancreatic carcinoma cell lines show that TGFb regulates cell cycle progression by a serine/threonine phosphatase-mediated inhibition of growth factor-induced activation of ERK2. This inhibition results in reduction of serum-induced proliferation of the epithelial pancreatic carcinoma cell lines PANC-1 and BxPC-3. Since BxPC-3 cells are characterized by smad4-deletion, we conclude that in these cells this inhibitory pathway represents a mechanism independent of Smad4 activation, while in other cells it can operate in addition to Smad4-mediated growth inhibition. MIA PaCa-2 cells, which lack a functional TGFb receptor type II, are not responsive to TGFb 1 . Mesenchymal NIH3T3 ®bro-blasts react with increased proliferation and Ras/Raf/ ERK activity to TGFb 1 treatment.
Results

TGFb 1 -induced inhibition of epithelial cell proliferation
To analyse the in¯uence of TGFb 1 on the proliferation of pancreatic carcinoma cell lines, DNA synthesis was measured in the presence and absence of TGFb 1 . Treatment of PANC-1 and BxPC-3 cells with increasing amounts of TGFb 1 (0.1 ± 10 ng/ml) resulted in a concentration-dependent reduction of cell proliferation as measured by [ 3 H]thymidine incorporation ( Figure 1) . Incubation of cells in growth medium containing 10% FCS and 10 ng/ml TGFb 1 resulted in a 30% reduction of cell proliferation (quadruplicate values, n=5). PANC-1 cells were more sensitive to TGFb 1 treatment than BxPC-3 cells, as demonstrated by the more pronounced eect of 0.1 and 1 ng/ml TGFb 1 ( Figure  1 ). Quiescent PANC-1 cells (cultured for 36 h in DMEM+1% BSA) exhibited a more prominent growth inhibition in response to TGFb 1 (45%, data not shown). In contrast to PANC-1 and BxPC-3, MIA PaCa-2 cells, the third pancreatic carcinoma cell line analysed in this study, did not respond to TGFb 1 even when high concentrations of ligand were used. Proliferation of NIH3T3 ®broblasts, which were used as a mesenchymal cell line, was not inhibited, but stimulated nearly twofold upon treatment with TGFb 1 (10 ng/ml). Addition of epidermal growth factor (EGF) (10 ng/ml) to serum-starved PANC-1 cells did not signi®cantly change the thymidine incorporation, but stimulated the DNA synthesis more than ®vefold in NIH3T3 ®broblasts (data not shown).
Expression of TGFb 1 -associated signaling molecules
To characterize the signal transduction pathway utilized by TGFb 1 , which accounts for the dierent eects in the analysed cell lines, we ®rst examined the presence and abundance of the TGFb receptors type I and II by Northern blot and immunoblot analyses. Receptor type speci®c Northern blot hybridizations (Figure 2a , left panel) revealed that both receptor proteins were expressed in PANC-1, BxPC-3 and NIH3T3 cells. The low signal intensity in NIH3T3 cells may be due to the human speci®c cDNA probes used in these experiments. In contrast, MIA PaCa-2 cells exhibited a distinct expression of TGFbRI transcript, but only a very low expression of TGFbRII mRNA with reduced molecular weight. These results were veri®ed on protein level by immunoblot analyses of membrane fractions. For PANC-1, BxPC-3, and NIH3T3, TGFbRI and TGFbRII proteins were clearly detectable. In contrast TGFbRI and TGFbRII were not traceable in MIA PaCa-2 (Figure 2a , right panel). TGFbRII receptors were homogenously distributed over the cell membrane for PANC-1 and BxPC-3 cells as revealed by immuno¯uorescence studies. There was no signal for MIA PaCa-2 cells (data not shown). Thus, PANC-1, BxPC-3, and NIH3T3 cells are endowed with both receptor subtypes, while MIA PaCa-2 cells do not express the TGFbRII subtype, which explains the lack of responsiveness towards TGFb 1 .
Smad proteins are substrates of TGFb type I receptor kinases and play a central role in transducing the receptor signals to target genes in the nucleus. Because Smad4/DPC4 is deleted or inactivated in a wide variety of pancreatic carcinomas, we analysed the content of Smad4 in the pancreatic carcinoma cell lines studied here. PANC-1 and MIA PaCa-2 showed marked Smad4 expression as analysed by RT ± PCR, Northern blot (data not shown), and Western blot analysis (Figure 2b ). In contrast, BxPC-3 cells exhibited no detectable Smad4, neither on mRNA nor on protein level, which is in agreement with data from the literature Schutte et al., 1996; Villanueva et al., 1998) .
TGFb 1 -induced inhibition of ERK2
To characterize the possible mechanisms involved in TGFb 1 -mediated reduction of pancreatic carcinoma cell proliferation, we analysed the in¯uence of TGFb 1 on the Ras-Raf-MEK-ERK/MAPK cascade, one of the best characterized signaling pathways involved in Figure 1 In¯uence of TGFb 1 on cell proliferation. Treatment of PANC-1 and BxPC-3 cells with TGFb 1 resulted in concentrationdependent inhibition of cell proliferation. MIA PaCa-2 cells, characterized by a lack of TGFb receptor type II, were unable to respond to TGFb. In contrast, NIH3T3 ®broblasts showed a marked increase in proliferation after treatment with TGFb 1 . Cell proliferation was measured by [ proliferation control. Activation of ERK1 and 2 is regulated by upstream protein kinases and Ras GTPases, which receive signals from the plasma membrane. As demonstrated in Figure 3a , treatment of serum-starved PANC-1, BxPC-3, MIA PaCa-2, as well as NIH3T3 cells with medium containing 10 ng/ml EGF led to a signi®cant stimulation of ERK2 activity in all cell lines. Only in NIH3T3 ®broblasts addition of 10 ng/ml TGFb 1 for 15 min resulted in a signi®cant ERK2 activation (2.2-fold), which is in line with the results of TGFb 1 -mediated ERK activation in mesenchymal cells from other laboratories (Axmann et al., 1998; Reimann et al., 1997) . Addition of TGFb 1 10 min before mitogenic stimulation (5 min with TGFb 1 plus EGF), resulted in marked reduction of EGFinduced MBP phosphorylation of PANC-1 (71%, To further characterize the in¯uence of TGFb 1 on growth factor-induced ERK2 activation, serum-starved PANC-1 and NIH3T3 cells were stimulated with serum. Treatment of cells for 5 min with medium containing 10% FCS (Figure 3b ) resulted in a 17-fold activation of ERK2 for PANC-1 and fourfold activation for NIH3T3 ®broblasts, which is approximately 50% of EGF-induced ERK activation. Prolonged treatment with TGFb 1 (17 h) had no signi®cant eect on ERK2 activation for PANC-1. Long-term treatment with TGFb 1 exhibited the same inhibitory eect on EGF-or FCS-induced kinase stimulation as pretreatment for 10 min. To examine the speci®city of the inhibitory eect of TGFb 1 for PANC-1, cells were incubated with TGFb 1 and a TGFb 1 -neutralizing antibody prior to mitogen treatment. Under these conditions, ERK2 activation was maintained as in control cells not treated with TGFb 1 (data not shown), con®rming the speci®city of the observed eects. Short term as well as prolonged TGFb 1 treatment did not alter the FCS-induced activation of ERK2 in NIH3T3 ®broblasts.
Influence of TGFb 1 on Ras and Raf activity
In order to analyse the signal transduction pathway leading to reduced ERK2 activity and proliferation in the pancreatic carcinoma cells in more detail, we examined the activity of Ras and Raf proteins, which are upstream activators of ERKs. The Ras-GTP content was estimated by pull-down experiments using a recombinant GST-fusion protein of the Ras-binding domain (RBD) of Raf as an activation speci®c probe for endogenous Ras-GTP (de Rooij and Bos, 1997). Ras-GTP binds to RBD with an anity three orders of magnitude higher than that of Ras-GDP (Herrmann et al., 1995) . The results of one representative assay out of four experiments are shown in Figure 4 . EGF stimulation of PANC-1 and BxPC-3 cells resulted in an increased amount of Ras-GTP which was about 3.5-times for PANC-1 and 6.8-times for BxPC-3 higher in comparison to quiescent control cells (Figure 4b ). Neither 10 min nor 17 h pretreatment with 10 ng/ml TGFb 1 was able to reduce this EGF-induced increase in Ras activation. Interestingly, TGFb 1 treatment by itself resulted in an increased Ras activation as determined 5 and 15 min after ligand addition ( Figure  4 ). In control experiments, where a neutralizing antibody against TGFb 1 was added together with the ligand TGFb, Ras activation was not altered with regard to quiescent cells. In NIH3T3 cells, the GDP/ GTP exchange on Ras was increased by EGF as well as by TGFb 1 . Cotreatment of ®broblasts with EGF and TGFb 1 did not result in additional Ras activation or in Ras inhibition as compared to treatment with EGF alone (Figure 4) .
Ras-GTP interacts with the serine/threonine kinase Raf, the ®rst protein kinase between Ras and ERK. Raf, which is activated by Ras, translocates to the plasma membrane. Since translocation from the cytoplasm to the inner surface of the plasma membrane is the ®rst indispensable step in Raf activation, we quanti®ed the amount of c-Raf-1 in cytosolic and membrane fractions of PANC-1, BxPC-3, and NIH3T3 cells by immunoblot analyses (Figure 5 ). Treatment of PANC-1 and BxPC-3 cells with EGF caused a 3.5-fold increase in membrane-associated c-Raf-1 in case of PANC-1 and a 4.6-fold in case of BxPC-3, respectively. The corresponding cytoplasmic fraction showed a clearly reduced c-Raf-1 content. In contrast to Ras activation, stimulation with TGFb 1 did not result in increased Raf activity. Pretreatment of PANC-1 and BxPC-3 cells with TGFb 1 before EGF-stimulation did not reduce the amount of c-Raf-1 at the plasma membrane. Equal loading of both fractions was veri®ed by reprobing the blots for b-catenin as a membrane and ERK2 as a cytoplasmic protein, respectively. NIH3T3 cells also reacted with enhanced Raf translocation to the membrane upon stimulation with 10 ng/ml EGF, although the eect was less dramatic compared to BxPC-3 cells. Preincubation of the cells with 10 ng/ml TGFb 1 prior to EGF addition did not result in decreased Raf activation. Furthermore, TGFb 1 itself induced Raf translocation to the plasma membrane. This is in line with observations, that TGFb 1 is able to enhance proliferation and ERK2 activity in ®broblasts. The TGFb 1 eect on c-Raf-1 was diminished by simultaneous addition of a neutralizing antibody against TGFb ( Figure 5 ).
Influence of TGFb 1 on ERK-dependent cell proliferation
To determine, if activated ERK2 is involved in TGFb 1 -mediated growth inhibition of pancreatic carcinoma cell lines, we inhibited ERK activation by using the MEK-1 speci®c inhibitor PD98059. Cell proliferation was quanti®ed by [ 3 H]thymidine incorporation. The inhibitor binds selectively to the inactive form of MEK-1 and prevents activation by upstream activators (Dudley et al., 1995) . As shown previously, 25 mM PD98059 is sucient for complete ERK inhibition but does not cause cytotoxic eects (Giehl et al., 2000) . Treatment of PANC-1, BxPC-3, and MIA PaCa-2 cells, incubated in medium containing 10% FCS, with PD98059 resulted in a concentration-dependent reduction of proliferation for all three cell lines. [ 3 H]thymidine incorporation was reduced by nearly 20% using 10 mM inhibitor, whereas 25 mM PD98059 resulted in 30 ± 40% decrease ( Figure 6 ). In PANC-1 cells, treatment with 25 mM PD98059 resulted in the same proliferation reduction as growth inhibition after TGFb 1 -treatment. Cotreatment of PANC-1 and BxPC-3 cells with 25 mM PD98059 and 10 ng/ml TGFb 1 resulted in the same growth inhibition as treatment with each inhibitor alone. MIA PaCA-2 cells were not responsive to TGFb 1 treatment, as shown above in Figure 1 , but needed activated ERK for proliferation.
The serine/threonine phosphatase inhibitor okadaic acid suppresses TGFb-induced ERK2 inhibition
To get further insights into the pathway utilized by TGFb to reduce growth factor-activated ERK2, we analysed the signi®cance of phosphatases by using speci®c phosphatase inhibitors. Addition of the cell-permeable tyrosine phosphatase inhibitor sodium vanadate (2.5 mM) during incubation of cells with TGFb, had no aect on either EGF-or/and TGFb-mediated ERK2 activity. In contrast, addition of okadaic acid (0.5 mM), a TGFb inhibits ERK activation K Giehl et al serine/threonine phosphatase inhibitor, resulted in a signi®cant reduction of the inhibitory eect of TGFb1 on EGF-activated ERK2 (Figure 7 ). This result points towards a serine/threonine phosphatase as a negative, TGFb-dependent, but Smad4-independent regulator for ERK2 activation, because this phosphatase-mediated pathway is utilized in PANC-1 as well as Smad4-de®cient BxPC-3 cells.
TGFb 1 -induced inhibition of ERK translocation to the nucleus
Activation of ERK, as one major signaling event responsible for cell cycle entry initiated by mitogenic stimuli, is closely connected with ERK translocation to the nucleus. To analyse, whether the TGFb 1 -induced inhibition of ERK2 activation is correlated with reduced ERK translocation to the nucleus, we examined the subcellular localization of ERK2 after EGF and/or TGFb 1 treatment for 15 min. ERK2 distribution in stimulated PANC-1 and BxPC-3 cells was investigated by immunohistochemistry, using an antiserum against ERK2. As shown in Figure 8 , EGF treatment resulted in a rapid transport of ERK2 to the nucleus of both cell lines (Figure 8b ,h). TGFb 1 alone induced no enhanced nuclear staining in PANC-1 (Figure 8c ) and BxPC-3 cells (Figure 8i) . Treatment of the cells with TGFb 1 in combination with EGF ( Figure 8d,j) prevented the mitogen-induced kinase translocation in PANC-1 and BxPC-3 cells. Comparable results were obtained using 10% FCS instead of EGF (data not shown). To exclude a general inhibition of nuclear transport activities, the ability of TGFb 1 to induce nuclear staining of Smad2/3 in PANC-1 cells was analysed, as shown in Figure 8e ,f. In summary, these data con®rm that TGFb 1 -induced growth inhibition of pancreatic carcinoma cells correlates with inactivation of ERK-dependent cell cycle progression.
Discussion
We have investigated the mechanism of TGFb 1 -mediated inhibition of growth factor-induced cell proliferation in epithelial pancreatic carcinoma cell lines. Our results suggest that TGFb 1 contributes to reduced cell proliferation by inhibiting mitogeninduced ERK activation independently of Smad4 proteins at least in pancreatic carcinoma cell lines. Activation of the mitogen-activated protein kinases ERK1 and ERK2 by growth factors and other mitogenic proteins represents an essential step in cell cycle re-entry of most cell types (Seger and Krebs, (Hocevar et al., 1999) . The BxPC-3 cell line, which is characterized by a homozygous deletion of smad4 gene (our data and (Villanueva et al., 1998) ) responds to TGFb 1 clearly but less eective as Smad4-positive PANC-1 cells. In addition to the proposed model (Attisano and Wrana, 1998; Heldin et al., 1997; Massague, 1998) , that TGFb exerts growth inhibitory and transcriptional repression To compare the eects of MEK inhibitor PD98059-and TGFb 1 -reduced DNA synthesis of PANC-1, BxPC-3, and MIA PaCa-2, the cells were treated with 10 ng/ml TGFb 1 , 10 mM or 25 mM PD98059 as described in Materials and methods. Incubation with PD98059 resulted in concentration-dependent decrease (20 ± 40%) of DNA synthesis in all cell lines. TGFb and PD98059 reacted as non-additive inhibitors. Mean values+s.e.mean of three independent experiments are expressed in per cent reduction in relation to untreated cells (100%) Figure 7 Serine/threonine phosphatase inhibitor neutralizes TGFb 1 -inhibition. Treatment of cells with 0.5 mM okadaic acid (OA), an inhibitor of serine/threonine phosphatases, resulted in suppression of the TGFb-induced inhibition of activated ERK2 in PANC-1 as well as in BxPC-3 cells. In contrast, inhibition of tyrosine phosphatases using 2.5 mM sodium vanadate (OV) had no eect on ERK activity. One representative assay out of three is shown Oncogene TGFb inhibits ERK activation K Giehl et al via Smad2/3 associated with Smad4, the pathway presented in this study suggest an additional antimitogenic eect independent of the latter protein.
Very recently, Dai et al. (1999) reported Smad4/ DPC4-independent, MEK1-dependent TGFb in¯u-ences on cell cycle progression, supporting the interpretation of our ®ndings. Dissection of TGFbregulated cell proliferation and TGFb/Smad-dependent gene expression is also described by Rodeck et al. (1999) . Melanoma cells, which were partially or completely resistant to TGFb-induced growth inhibition, exhibited functional intact Smad-dependent gene expression. These observations underscore the uncoupling of the TGFb growth response from the transcriptional response pathway.
The requirement of functional TGFb receptors for the growth inhibitory eect of TGFb, as demonstrated in this study, is manifested by using TGFbRII-de®cient MIA PaCa-2 cells, as shown here and by Freeman et al. (1995) . Stimulation of MIA PaCa-2 cells with TGFb did not result in reduced proliferation or inhibition of growth factor-induced ERK2 activation.
In contrast to the pathway suggested above, Massague and colleagues show an inverse pathway in which TGFb signaling via Smads can be inhibited by Ras-induced ERK activation (Calonge and Massague, 1999; Kretzschmar et al., 1999) . These divergent ®ndings implicate a ®ne tuned, eventually cell type and signal-speci®c connection between the Ras/ERK and TGFb/Smad pathways. The involvement of Ras in TGFb-mediated signal transduction was also shown by Mulder and Morris (1992) . TGFb-sensitive, non-transformed intestinal epithelial cells (IEC 4-1) showed a subtle activation of ERK1 (p44MAPK) after addition of TGFb 2 to proliferating, but serum-starved cells (Hartsough and Mulder, 1995) .
The inhibition of growth factor-induced ERK2 stimulation in our system is not caused by reduction of c-Raf-1 and Ras activation due to mitogen exposure. The TGFb 1 -induced activation of Ras, but not c-Raf-1 in pancreatic carcinoma cells might aect other, c-Raf-1 independent regulatory pathways, which are currently unknown. The results presented here suggest a serine/threonine phosphatase as a TGFbdependent, but Ras/Raf-independent regulator of ERK, which directly or indirectly mediates ERK2 inactivation. Although this phosphatase is not yet identi®ed, results obtained by Griswold-Prenner et al. (1998) show that the regulatory subunit Ba of protein phosphatase 2A (PP2A) enhances the growth inhibitory activity of TGFb in a receptor-dependent manner. This proposes PP2A as a likely candidate, because the enzyme is also characterized by its ability to dephosphorylate activated MEK and ERK (Alessi et al., 1995) .
In contrast to the epithelial cell system, mesenchymal cells respond dierently to TGFb as shown here and by others (Axmann et al., 1998; Reimann et al., 1997) . To support the speci®city of the observed eects in epithelial PANC-1 and BxPC-3 cells, we analysed NIH3T3 cells for comparison. TGFb 1 increased the [ 3 H]thymidine incorporation in mesenchymal cells and activated Ras, c-Raf-1 and ERK2. Cotreatment of cells with EGF and TGFb 1 resulted in neither reduced mitogen-induced ERK2 activation nor prevention of nuclear translocation.
In conclusion, TGFb 1 can interfere with growth factor-induced cell proliferation via ERK2 inactivation in epithelial pancreatic carcinoma cells. This pathway operates independently of Smad4 and can therefore function in addition to Smad4-dependent growth inhibition. 
Materials and methods
Antibodies and growth factors
Neutralizing TGFb antiserum (AB 101 NA) and anti-TGFb receptor type II (AF 241 NA) were obtained from R&D Systems (Wiesbaden, Germany), antibodies against TGFb receptor type I (T-19), ERK2 (C14), MEK-1 (C-18), Smad2/3 and GST (Z-5) were from Santa Cruz Biotechnology (Santa Cruz, CA, USA), anti-pan-Ras antibody (Ab-3) was from Oncogene Sciences (Cambridge, MA, USA), anti-b-catenin from Sigma (Deisenhofen, Germany), anti-Smad4 from Transduction Laboratories (San Diego, CA, USA), and polyclonal c-Raf-1 antiserum from Promega (Mannheim, Germany). The growth factors EGF and TGFb1 were obtained from PeproTech (Rocky Hill, NJ, USA) and the MEK inhibitor PD98059 was purchased from NEB (Beverly MA, USA). The phosphatase inhibitors okadaic acid and sodium vanadate were from Sigma (Deisenhofen, Germany).
Cell lines and culture conditions
The cell lines PANC-1 (ATCC, CRL 1469), BxPC-3 (ATCC, CRL 1687), MIA PaCa-2 (ATCC, CRL 1420) and NIH3T3 (ATCC, CRL 1658) were obtained from American Type Culture Collection (Rockville, MD, USA). Epithelial cells were grown in DMEM complemented with 10% fetal calf serum (FCS) (Life Technologies, Karlsruhe, Germany), 1% non-essential amino acids and 1% L-glutamine. NIH3T3 cells were cultured in DMEM containing 10% donor calf serum (Life Technologies) instead of FCS. Cells were incubated at 378C in a humidi®ed atmosphere with 10% CO 2 . For Ras, cRaf and ERK assays cells were stimulated with 10 ng/ml EGF or TGFb 1 . To analyse the TGFb in¯uence on EGFinduced enzymatic activity, the cells were stimulated with 10 ng/ml EGF and 10 ng/ml TGFb 1 for 5 min after a preincubation for 10 min with 10 ng/ml TGFb 1 . To inhibit protein phosphatases, cells were incubated 15 min prior to addition of growth factors with 2.5 mM sodium vanadate or 0.5 mM okadaic acid.
Proliferation assay
DNA synthesis was determined by [methyl 3 H]thymidine incorporation as described in (Menke et al., 1999) . Brie¯y, cells were plated in 24-well plates (5610 4 cells/well) and allowed to attach for 24 h. Serum-starvation was performed by incubation with DMEM+1% bovine serum albumin (BSA) for 36 h or 12 h for NIH3T3, respectively, followed by stimulation with assay medium (DMEM+1% BSA+growth factors and inhibitors) for additional 36 h. [ 3 H]thymidine (1 mCi/well) was added for the last 24 h. Acid-insoluble radioactivity incorporated into protein was determined by liquid scintillation counting after solubilization in 0.1% NaOH, 1% sodium dodecyl sulfate (SDS).
ERK activity assay
ERK activity was quanti®ed in total RIPA cell lysates (50 mM Tris/HCl, pH 7.2, 150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 2 mM sodium orthovanadate, 25 mM b-glycerophosphate, 10 mM sodium pyrophosphate, 400 mM aprotinin) in an in vitro kinase reaction using a synthetic peptide (-APRTPGGRR-) derived from myelin basic protein (MBP) as kinase substrate (Gardner et al., 1993) . ERK2 was immunoprecipitated from 0.5 mg of cellular protein for 2 h at 48C using 25 ml of Protein-A agarose and 7 ml of ERK2 antibody. The kinase reaction was performed in kinase buer (15 mM Tris/HCl, pH 7.2, 15 mM MgCl 2 , 1 mM DTT), started by adding 2 mM ATP, 30 mg of MBP peptide, and 2 mCi [g 32 P]ATP (5000 Ci mmol), and carried out for 10 min at 378C. Samples were spotted onto P81 phosphocellulose ®lter. Filters were washed three times in 180 mM phosphoric acid and bound radioactivity was determined by Cerenkov radiation.
Ras-GTP binding assay
GTP-bound form of Ras was detected by using GST-RBD as an activation-speci®c probe for endogenous Ras-GTP (de Rooij and Bos, 1997) . Con¯uent cells were serum-starved for 36 h (NIH3T3 for 12 h) in minimal medium (DMEM + 1% BSA) and stimulated with assay medium. Cells (1 ± 2610 7 / 100 mm cell culture dish) were washed with phosphate buered saline (PBS) and lysed in 500 ml Ras-RIPA buer (50 mM Tris/HCl, pH 8.0, 150 mM NaCl, 0.5% sodium deoxycholate, 1% NP-40, 0.1% SDS, 1 mM leupeptin, 1 mM phenylmethylsulfonyl¯uoride). Protein concentration of cleared cell lysate was determined by bicinchoninic acid assay (Pierce; Rockford, USA). Glutathione-Sepharose 4B (Pharmacia; Uppsala, Sweden) was preincubated with 150 ml GST-RBD extract at room temperature for 30 min. Recombinant GST-RBD was prepared as described in (de Rooij and Bos, 1997) . Cell lysate (1 mg) was added to washed beads and incubated at 48C for 2 h by end-over-end rotation. Proteins were separated on 12.5% SDS-polyacrylamide gel and subsequently transferred to nitrocellulose membrane (Schleicher & SchuÈ ll, Dassel, Germany). Equal loading was controlled by immunostaining of GST-RBD using anti-GST antibody. Precipitated endogenous Ras was detected by using the monoclonal pan-Ras (Ab-3) antibody, peroxidase-coupled goat anti-mouse antiserum and ECL development (Pierce, Rockford, USA).
Raf assay
Raf activation was estimated by quantifying the amount of cRaf-1 in cytosolic and membrane fractions. Cells were treated with assay medium as described for Ras assay and were then homogenized in KRH buer (100 mM KCl, 10 mM PIPES, pH 7.3, 3.5 mM MgCl 2 , 3 mM NaCl, 5 mM aprotinin, 1 mM pefabloc, 10 mM leupeptin, 5 mM sodium vanadate and 5 mM soybean trypsin inhibitor). Nuclei and unbroken cells were removed by centrifugation (200 g, 5 min). Cytosolic and membrane fractions were separated by centrifugation at 100 000 g and 48C for 30 min. Membranes were further puri®ed by resuspending the pellet in KRH buer, followed by high speed centrifugation at 100 000 g and 48C for 1 h. Fractions of 30 mg protein were analysed for c-Raf-1 content by Western blotting as described below. Equal loading was controlled by restaining the blots for b-catenin in case of membrane fractions and ERK2 of cytosolic samples.
Protein determination by Western blots
SDS-polyacrylamide gel electrophoresis (PAGE) was performed according to standard procedures (Laemmli, 1970) . Sixty mg of lysate were separated for Smad4 detection and 20 mg of the membrane fraction, produced as described above, for TGFb receptor analyses. Proteins were blotted by semidry technique onto nitrocellulose membranes (Schleicher & SchuÈ ll, Dassel, Germany) and immunoreactive proteins were visualized by using the enhanced chemiluminescence (ECL) Western blotting detection system (Pierce, Rockford, USA) or by using alkaline phosphatase-conjugated antibodies (Dianova, Hamburg, Germany) and nitroblue tetrazolium/ bromo-chloro-indoyl phosphate staining.
RNA studies
RNA was extracted using the RNeasy Midi Kit from Qiagen (Hilden, Germany) according to manufacturer's instructions. Poly(A)+ RNA was isolated with Oligotex Kit (Qiagen). For Northern blot detection, 4 mg of poly(A)+ RNA were separated by electrophoresis and transferred on Hybond-N membranes (Amersham, Braunschweig, Germany) as described in (Menke et al., 1997) . Equal loading was veri®ed by 18S rRNA hybridization, using a probe kindly provided by Dr T Gress (University of Ulm, Germany). Humanspeci®c cDNA probes for TGFbRI and TGFbRII (ALK5) were kindly provided by Dr MG Brattain (Medical College of Ohio, Toledo, OH, USA), human-speci®c Smad4 cDNA was a kind gift of Dr S Hahn (University of Bochum, Germany). Blots were hybridized with 32 P-dCTP-labeled cDNA probes as described earlier (Menke et al., 1997) . For RT ± PCR, 10 mg of total RNA were reversely transcribed using oligo-dT primer and reverse transcriptase (Superscript, Life Technologies, Karlsruhe, Germany). Complementary DNA was synthesized for 60 min at 378C and stopped by incubation for 15 min at 708C. PCR was performed with 2.5 mM MgCl 2 and 2.5 U Taq DNA Polymerase (Sigma). The ampli®cation protocol was as follows: 35 cycles at 948C for 1 min, 528C for 1 min, 728C for 2 min, followed by a ®nal extension time of 10 min at 728C. The PCR primers were designed based on the published cDNA sequence for Smad4 (sense 5'-ATGGACAATATGTCTATTA-3', antisense 5'-TCAGTCTAAAGGTTGTGG-3'). As a control, b-actin mRNA was ampli®ed from the used cDNAs with the following ampli®cation protocol: 15 cycles at 948C for 45 s, 608C for 1 min, 728C for 1.5 min, followed by a ®nal extension time of 10 min at 728C. The PCR primers were 5'-
